Literature DB >> 20696318

Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.

Abid Oueslati1, Margot Fournier, Hilal A Lashuel.   

Abstract

A better understanding of the molecular and cellular determinants that influence the pathology of Parkinson's disease (PD) is essential for developing effective diagnostic, preventative and therapeutic strategies to treat this devastating disease. A number of post-translational modifications to alpha-syn are present within the Lewy bodies in the brains of affected patients and transgenic models of PD and related disorders. However, whether disease-associated alpha-syn post-translational modifications promote or inhibit alpha-syn aggregation and neurotoxicity in vivo remains unknown. Herein, we summarize and discuss the major disease-associated post-translational modifications (phosphorylation, truncation and ubiquitination) and present our current understanding of the effect of these modifications on alpha-syn aggregation and toxicity. Elucidating the molecular mechanisms underlying post-translation modifications of alpha-syn and the consequences of such modifications on the biochemical, structural, aggregation and toxic properties of the protein is essential for unravelling the molecular basis of its function(s) in health and disease. Furthermore, the identification of the natural enzymes involved in regulating the post-translational modifications of alpha-synuclein will yield novel and more tractable therapeutic targets to treat PD and related synucleinopathies. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696318     DOI: 10.1016/S0079-6123(10)83007-9

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  124 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  Semisynthetic, site-specific ubiquitin modification of α-synuclein reveals differential effects on aggregation.

Authors:  Franziska Meier; Tharindumala Abeywardana; Abhinav Dhall; Nicholas P Marotta; Jobin Varkey; Ralf Langen; Champak Chatterjee; Matthew R Pratt
Journal:  J Am Chem Soc       Date:  2012-03-14       Impact factor: 15.419

Review 3.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

Review 4.  Dynamic structural flexibility of α-synuclein.

Authors:  Danielle E Mor; Scott E Ugras; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Neurobiol Dis       Date:  2015-12-31       Impact factor: 5.996

Review 5.  Chaperone-mediated autophagy: roles in disease and aging.

Authors:  Ana Maria Cuervo; Esther Wong
Journal:  Cell Res       Date:  2013-11-26       Impact factor: 25.617

Review 6.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

7.  Site-specific differences in proteasome-dependent degradation of monoubiquitinated α-synuclein.

Authors:  Tharindumala Abeywardana; Yu Hsuan Lin; Ruth Rott; Simone Engelender; Matthew R Pratt
Journal:  Chem Biol       Date:  2013-10-24

Review 8.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

9.  The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity.

Authors:  Ossama Khalaf; Bruno Fauvet; Abid Oueslati; Igor Dikiy; Anne-Laure Mahul-Mellier; Francesco Simone Ruggeri; Martial K Mbefo; Filip Vercruysse; Giovanni Dietler; Seung-Jae Lee; David Eliezer; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

Review 10.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.